A core biopsy of the breast is a minimally invasive procedure that uses a hollow needle to remove small cylinders of tissue from a suspicious area in the breast. It’s the most common way doctors diagnose breast cancer and other breast conditions, and it’s typically done in an outpatient setting with local anesthesia in 20 to 60 minutes.
Unlike a fine-needle aspiration, which draws out individual cells through a very thin needle, a core biopsy uses a larger needle (usually 14-gauge for standard biopsies or 8- to 11-gauge for vacuum-assisted versions) to extract intact tissue samples. Those small cylinders of tissue let a pathologist examine the architecture of the cells, how they’re arranged and how they relate to each other, which is critical for determining not just whether cancer is present but what type and grade it is.
Why a Core Biopsy Gets Recommended
Imaging alone can’t confirm whether a breast abnormality is cancerous. After a mammogram, ultrasound, or MRI flags something suspicious, radiologists use a scoring system called BI-RADS to rate how likely a finding is to be cancer. Any lesion with a likelihood of malignancy greater than 2% is classified as BI-RADS category 4 or higher, and biopsy is recommended. Category 4 itself covers a wide range: 4a means low suspicion (2 to 10% chance), 4b means moderate suspicion (10 to 50%), and 4c means high suspicion (50 to 95%). Category 5 lesions, those that look highly suggestive of malignancy, also require tissue sampling to confirm the diagnosis before treatment planning begins.
Common reasons you might be referred for a core biopsy include a new mass found on imaging, a cluster of tiny calcium deposits (calcifications) on a mammogram, an area of distorted tissue, or a region that lights up unusually on an MRI. Sometimes a lump you or your doctor can feel will also prompt a biopsy, even if imaging looks relatively reassuring.
How the Needle Is Guided to the Right Spot
The needle doesn’t go in blind. Your radiologist uses real-time imaging to position it precisely within the suspicious area. The type of imaging guidance depends on which method best shows the abnormality.
Ultrasound guidance is the most commonly used approach. If the lesion is visible on ultrasound, this method is usually preferred because it lets the radiologist watch the needle in real time, confirm it passes through the center of the target, and adjust as needed. You’ll typically lie on your back or side while a high-frequency probe is held against your skin.
Stereotactic (mammography) guidance is used when an abnormality shows up on a mammogram but can’t be seen on ultrasound, which is often the case with calcifications. The system takes images from two angles to calculate the exact three-dimensional coordinates of the target. A newer version uses 3D tomosynthesis imaging instead of traditional 2D mammography to pinpoint depth more precisely. During this type of biopsy, your breast is compressed similarly to a mammogram.
MRI guidance is reserved for lesions that are only visible on breast MRI. You lie face down on a special table, and a grid is placed along the side of your breast. Computer software calculates the distance from the skin to the lesion, and the needle is guided in using those coordinates. MRI-guided biopsies typically use a vacuum-assisted technique to collect tissue.
What Happens During the Procedure
The procedure starts with local anesthesia, a numbing injection at the biopsy site. Once the area is numb, your radiologist makes a tiny skin incision, usually just a few millimeters, to allow the biopsy needle to pass through. For a standard core biopsy, a spring-loaded needle fires forward to cut a small cylinder of tissue. You may hear a clicking or snapping sound when it fires. This is repeated several times to collect multiple samples, typically three to six or more, depending on the size and nature of the abnormality.
Vacuum-assisted devices work slightly differently. Instead of firing a spring-loaded needle, they use suction to pull tissue into the needle’s cutting chamber, allowing the radiologist to collect larger and more numerous samples through a single insertion. These devices use wider needles (8- to 11-gauge compared to 14-gauge for standard core biopsies) and are especially useful for sampling calcifications or small lesions.
After the tissue samples are collected, a small metallic marker clip is placed at the biopsy site. This clip serves an important purpose: it marks the exact location that was sampled so it can be found again on future imaging or used to guide a surgeon if additional treatment is needed. The clip is compatible with MRI and can also be seen on ultrasound and mammography. Once the clip is in place, pressure is applied to the site to control bleeding, and a small adhesive bandage or compression dressing is placed over the incision. Stitches are rarely needed.
Recovery and What to Expect Afterward
Most people go home shortly after the procedure and can return to normal daily activities within a day or two. You should avoid strenuous activities for about three days, including heavy housework, yard work, and exercise. Some bruising and mild swelling around the biopsy site are normal and can last a week or two. Breast tissue is fatty, which tends to bruise easily.
Over-the-counter pain relievers are usually enough to manage any discomfort. Keep the area clean and dry, and watch for signs of infection: increasing pain, swelling, redness, or warmth around the incision. These are uncommon but worth knowing about.
How Long Results Take
Pathology results from a core biopsy typically come back within a few days to a week, though the timeline varies. Breast tissue contains a lot of fat, which means the preservative solution used in the lab takes longer to penetrate the samples, sometimes adding an extra day of processing. If the pathologist needs additional staining techniques to characterize the cells more precisely, that can add another day or two. In cases where a second pathologist reviews the slides, or specialized molecular testing is ordered, results may take two to three weeks.
How Accurate Core Biopsies Are
Core biopsies are highly accurate, but they aren’t perfect. Ultrasound-guided core biopsies have the lowest false-negative rate at about 1.7%, meaning cancer is missed in fewer than 2 out of 100 cases. Stereotactic-guided biopsies, often used for calcifications that are inherently harder to sample, have a false-negative rate around 9%. The overall sensitivity of image-guided core biopsies ranges from 90 to 99%, depending on the technique and the type of lesion being sampled.
This is why your care team compares your biopsy results against your imaging findings. If the pathology result doesn’t match what the imaging suggested (for example, a highly suspicious-looking lesion comes back benign), your doctor may recommend a repeat biopsy or surgical excision to make sure nothing was missed.
Understanding Your Results
Results generally fall into three broad categories: benign (not cancer), malignant (cancer), or high-risk. A benign result means no cancer was found in the tissue samples. A malignant result will include details about the type of cancer, its grade, and often its hormone receptor status, all of which guide treatment planning.
The middle category, high-risk lesions, can be the most confusing. These are findings that aren’t cancer but carry an elevated risk of becoming cancer or of having cancer nearby that wasn’t captured in the biopsy samples. Atypical ductal hyperplasia (ADH) is one of the most common high-risk findings and carries the highest risk of malignant transformation among this group. For ADH, papillomas with atypical cells, and certain other high-risk lesions, surgical removal of the area is still generally recommended. This isn’t because cancer has been found, but because a core biopsy samples only a portion of the abnormality, and removing the full area ensures nothing more concerning is hiding adjacent to what was sampled.
For other high-risk findings where the abnormality was fully removed during the biopsy and no atypical cells are present, close surveillance with regular imaging may be sufficient. These decisions are typically made by a multidisciplinary team that reviews your imaging, pathology, and personal risk factors together.